These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 38608457)

  • 1. Omicron variants of SARS-CoV-2: Epidemiological and clinical insights from a tertiary care center in Saudi Arabia.
    Dubaie B; Aldayel A; Alwethinani S; Alhuthil R; Alhamlan F; Alghamdi S; Alsuhaibani M; Aljumaah S; AlYabes O; AlBanyan E; Al-Hajjar S
    J Infect Public Health; 2024 Jun; 17(6):961-966. PubMed ID: 38608457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relative vaccine protection, disease severity, and symptoms associated with the SARS-CoV-2 omicron subvariant BA.2.86 and descendant JN.1 in Denmark: a nationwide observational study.
    Moustsen-Helms IR; Bager P; Larsen TG; Møller FT; Vestergaard LS; Rasmussen M; Hansen CH;
    Lancet Infect Dis; 2024 May; ():. PubMed ID: 38761806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Broad immunogenicity to prior SARS-CoV-2 strains and JN.1 variant elicited by XBB.1.5 vaccination in nursing home residents.
    Abul Y; Nugent C; Vishnepolskiy I; Wallace T; Dickerson E; Holland L; Esparza I; Winkis M; Wali KT; Chan PA; Baier RR; Recker A; Kaczynski M; Kamojjala S; Pralea A; Rice H; Osias O; Oyebanji OA; Olagunju O; Cao Y; Li CJ; Roederer A; Pfeifer WM; King CL; Bosch J; Nanda A; McNicoll L; Mujahid N; Raza S; Tyagi R; Wilson BM; White EM; Canaday DH; Gravenstein S; Balazs AB
    medRxiv; 2024 Mar; ():. PubMed ID: 38585784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics and clinical manifestations of patients, including organ transplant patients, during the surge of JN.1: Insights from Saudi Arabia.
    Obeid DA; Al-Qahtani AA; Almaghrabi RS; Alahideb BM; Alharbi LA; AlAbdulkareem MA; Almadi TM; Alsanea MS; Althawadi SI; Altamimi SA; Alhamlan FS
    J Infect Public Health; 2024 Jul; 17(7):102452. PubMed ID: 38820895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity - IVY Network, 26 Hospitals, October 18, 2023-March 9, 2024.
    Ma KC; Surie D; Lauring AS; Martin ET; Leis AM; Papalambros L; Gaglani M; Columbus C; Gottlieb RL; Ghamande S; Peltan ID; Brown SM; Ginde AA; Mohr NM; Gibbs KW; Hager DN; Saeed S; Prekker ME; Gong MN; Mohamed A; Johnson NJ; Srinivasan V; Steingrub JS; Khan A; Hough CL; Duggal A; Wilson JG; Qadir N; Chang SY; Mallow C; Kwon JH; Parikh B; Exline MC; Vaughn IA; Ramesh M; Safdar B; Mosier J; Harris ES; Shapiro NI; Felzer J; Zhu Y; Grijalva CG; Halasa N; Chappell JD; Womack KN; Rhoads JP; Baughman A; Swan SA; Johnson CA; Rice TW; Casey JD; Blair PW; Han JH; Ellington S; Lewis NM; Thornburg N; Paden CR; Atherton LJ; Self WH; Dawood FS; DeCuir J
    medRxiv; 2024 Jun; ():. PubMed ID: 38883802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BNT162b2 vaccine protection against omicron and effect of previous infection variant and vaccination sequence among children and adolescents in Singapore: a population-based cohort study.
    Yung CF; Pang D; Kam KQ; Lye DC; Ong B; Chong CY; Tan KB
    Lancet Child Adolesc Health; 2023 Jul; 7(7):463-470. PubMed ID: 37201540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct patterns of SARS-CoV-2 BA.2.87.1 and JN.1 variants in immune evasion, antigenicity, and cell-cell fusion.
    Li P; Liu Y; Faraone JN; Hsu CC; Chamblee M; Zheng Y-M; Carlin C; Bednash JS; Horowitz JC; Mallampalli RK; Saif LJ; Oltz EM; Jones D; Li J; Gumina RJ; Liu S-L
    mBio; 2024 May; 15(5):e0075124. PubMed ID: 38591890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of Omicron XBB.1.5 vaccine against infection with SARS-CoV-2 Omicron XBB and JN.1 variants, prospective cohort study, the Netherlands, October 2023 to January 2024.
    Huiberts AJ; Hoeve CE; de Gier B; Cremer J; van der Veer B; de Melker HE; van de Wijgert JH; van den Hof S; Eggink D; Knol MJ
    Euro Surveill; 2024 Mar; 29(10):. PubMed ID: 38456217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasion.
    Planas D; Staropoli I; Michel V; Lemoine F; Donati F; Prot M; Porrot F; Guivel-Benhassine F; Jeyarajah B; Brisebarre A; Dehan O; Avon L; Bolland WH; Hubert M; Buchrieser J; Vanhoucke T; Rosenbaum P; Veyer D; Péré H; Lina B; Trouillet-Assant S; Hocqueloux L; Prazuck T; Simon-Loriere E; Schwartz O
    Nat Commun; 2024 Mar; 15(1):2254. PubMed ID: 38480689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical phenotypes and outcomes associated with SARS-CoV-2 Omicron sublineage JN.1 in critically ill COVID-19 patients: a prospective, multicenter cohort study in France, November 2022 to January 2024.
    de Prost N; Audureau E; Guillon A; Handala L; Préau S; Guigon A; Uhel F; Le Hingrat Q; Delamaire F; Grolhier C; Tamion F; Moisan A; Darreau C; Thomin J; Contou D; Henry A; Daix T; Hantz S; Saccheri C; Giordanengo V; Pham T; Chaghouri A; Bay P; Pawlotsky JM; Fourati S;
    Ann Intensive Care; 2024 Jun; 14(1):101. PubMed ID: 38940865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolutionary and Phylogenetic Dynamics of SARS-CoV-2 Variants: A Genetic Comparative Study of Taiyuan and Wuhan Cities of China.
    Hussain B; Wu C
    Viruses; 2024 Jun; 16(6):. PubMed ID: 38932199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early Estimates of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Attributable to Co-Circulating Omicron Variants Among Immunocompetent Adults - Increasing Community Access to Testing Program, United States, September 2023-January 2024.
    Link-Gelles R; Ciesla AA; Mak J; Miller JD; Silk BJ; Lambrou AS; Paden CR; Shirk P; Britton A; Smith ZR; Fleming-Dutra KE
    MMWR Morb Mortal Wkly Rep; 2024 Feb; 73(4):77-83. PubMed ID: 38300853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolving Epidemiology of Pediatric Respiratory Syncytial Virus (RSV) Cases Around COVID-19 Pandemic: Impact and Clinical Insights, Retrospective Cohort Study.
    Gashgarey D; Alsuhaibani M; Alhuthil R; Alhabshan H; Alabdulqader A; Badran R; Balhmar A; Aldawood H; AlBanyan EA; AlGhamdi S; AlJumaah S; AlYabes O; Al-Hajjar S
    J Epidemiol Glob Health; 2024 Jun; 14(2):319-326. PubMed ID: 38573464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tracking SARS-CoV-2 variants during the 2023 flu season and beyond in Lebanon.
    Kodsi IA; Rayes DE; Koweyes J; Khoury CA; Rahy K; Thoumi S; Chamoun M; Haddad H; Mokhbat J; Tokajian S
    Virus Res; 2024 Jan; 339():199289. PubMed ID: 38036064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of SARS-CoV-2 genomic surveillance data during the Delta and Omicron waves at a Saudi tertiary referral hospital.
    Obeid D; Al-Qahtani A; Almaghrabi R; Alghamdi S; Alsanea M; Alahideb B; Almutairi S; Alsuwairi F; Al-Abdulkareem M; Asiri M; Alshukairi A; Alkahtany J; Altamimi S; Mutabagani M; Althawadi S; Alanzi F; Alhamlan F
    J Infect Public Health; 2023 Feb; 16(2):171-181. PubMed ID: 36543031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5- and XBB/XBB.1.5-Related Sublineages Among Immunocompetent Adults - Increasing Community Access to Testing Program, United States, December 2022-January 2023.
    Link-Gelles R; Ciesla AA; Roper LE; Scobie HM; Ali AR; Miller JD; Wiegand RE; Accorsi EK; Verani JR; Shang N; Derado G; Britton A; Smith ZR; Fleming-Dutra KE
    MMWR Morb Mortal Wkly Rep; 2023 Feb; 72(5):119-124. PubMed ID: 36730051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Characteristics and Outcomes Among Adults Hospitalized with Laboratory-Confirmed SARS-CoV-2 Infection During Periods of B.1.617.2 (Delta) and B.1.1.529 (Omicron) Variant Predominance - One Hospital, California, July 15-September 23, 2021, and December 21, 2021-January 27, 2022.
    Modes ME; Directo MP; Melgar M; Johnson LR; Yang H; Chaudhary P; Bartolini S; Kho N; Noble PW; Isonaka S; Chen P
    MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(6):217-223. PubMed ID: 35143466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. JN.1 variant in enduring COVID-19 pandemic: is it a variety of interest (VoI) or variety of concern (VoC)?
    Kamble P; Daulatabad V; Singhal A; Ahmed ZS; Choubey A; Bhargava S; John NA
    Horm Mol Biol Clin Investig; 2024 Jun; 45(2):49-53. PubMed ID: 38622986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomic surveillance and vaccine response to the dominant SARS-CoV-2 XBB lineage in Rio Grande do Sul.
    Piccoli BC; Y Castro TR; Tessele LF; Casarin BC; Seerig AP; Vieira AA; Santos VT; Schwarzbold AV; Trindade PA
    Sci Rep; 2024 Jul; 14(1):16831. PubMed ID: 39039137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasion.
    Planas D; Staropoli I; Michel V; Lemoine F; Donati F; Prot M; Porrot F; Guivel-Benhassine F; Jeyarajah B; Brisebarre A; Dehan O; Avon L; Boland WH; Hubert M; Buchrieser J; Vanhoucke T; Rosenbaum P; Veyer D; Péré H; Lina B; Trouillet-Assant S; ; Hocqueloux L; Prazuck T; Simon-Loriere E; Schwartz O
    bioRxiv; 2024 Feb; ():. PubMed ID: 38045308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.